Bayer Rules Out Monsanto Spin-Off as Roundup Lawsuits Continue to Mount

Bayer has no plans to spin off Monsanto despite ongoing legal challenges linked to its Roundup weedkiller, according to a company representative speaking at the Wall Street Journal’s Global Food Forum. While the possibility of restructuring remains an option for the future, Bayer is currently focused on improving business performance and addressing the growing number of Roundup lawsuits.

Bayer CEO Bill Anderson emphasized the serious impact that glyphosate litigation could have on the company’s operations. Speaking at the event, Anderson warned that without a resolution to the legal disputes surrounding glyphosate, the future of U.S.-produced glyphosate could be at risk. Bayer currently remains the only domestic producer of glyphosate, although significant quantities of generic glyphosate products are imported from China.

The legal issues stem from Bayer’s $63 billion acquisition of Monsanto in 2018, which included ownership of the Roundup herbicide brand. Since the acquisition, Bayer has faced thousands of lawsuits from consumers who claim the company failed to provide adequate warnings about potential cancer risks associated with glyphosate exposure. The company estimates that approximately 100,000 plaintiffs are involved in ongoing litigation.

To manage the legal pressure, Bayer has pursued several strategies, including large settlement agreements and efforts to influence state-level legislation. The company is also seeking relief through the U.S. Supreme Court, where it is appealing a Missouri jury verdict that awarded $1.25 million to a plaintiff who linked years of Roundup exposure to non-Hodgkin lymphoma.

In addition, Bayer has proposed a $7.25 billion settlement aimed at resolving most remaining Roundup claims, though some plaintiffs continue to challenge the agreement. The company has also supported legislative initiatives in multiple states designed to limit lawsuits against pesticide manufacturers. While some states, including North Dakota, Kentucky, and Georgia, have approved such measures, Bayer recently faced a setback when the U.S. House of Representatives removed a liability protection provision from its latest Farm Bill proposal. The Senate has yet to consider the legislation.

As Bayer continues to battle Roundup litigation, investors and industry observers remain focused on how the company will navigate legal risks while maintaining its position in the global agriculture and crop protection market.